Aprea Therapeutics Appoints Eugene Kennedy as Chief Medical Advisor Following Early Clinical Success with WEE1 Inhibitor
核心洞察
Aprea Therapeutics has appointed industry veteran Eugene Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept demonstrated in its ongoing Phase 1 study of WEE1 (搜索) inhibitor APR-1051.
Dr. Kennedy brings over 20 years of oncology clinical development experience and has previously served as Chief Medical Officer at multiple biotechnology companies including Carisma Therapeutics and Galera Therapeutics (搜索).
The appointment strengthens Aprea's clinical leadership as the company advances dose escalation and refines patient selection for its DNA damage response program targeting multiple solid tumor types.
Aprea Therapeutics has appointed Eugene Kennedy, MD, as Chief Medical Advisor at a pivotal moment for the clinical-stage biopharmaceutical company, following recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 (搜索) inhibitor APR-1051 in patients with advanced solid tumors.
Dr. Kennedy is a highly accomplished physician scientist and biopharmaceutical executive with more than 20 years of experience spanning oncology clinical development, regulatory strategy, and senior corporate leadership across both public and private biotechnology companies. Aprea believes his engagement will strengthen the company's clinical leadership as it advances dose escalation and refines patient selection for its WEE1 (搜索)-focused DNA damage response program.
Strategic Appointment Timing
"We are excited to bring on a high caliber advisor such as Dr. Kennedy who has an extensive background in oncology drug development and experience across multiple stages of clinical development," said Oren Gilad, PhD, Chief Executive Officer of Aprea Therapeutics. "His track record in leading and advancing complex oncology programs, working closely with regulators, and supporting data-driven decisions will be invaluable as we build on our recent early clinical proof-of-concept, optimize dose and patient selection in our WEE1 (搜索) program and advance our DDR pipeline toward key clinical and regulatory milestones."
Dr. Kennedy expressed enthusiasm about the appointment, stating, "DDR inhibition has the potential to fundamentally change how we approach certain difficult-to-treat cancers, and I am aligned with Aprea's strategy to pursue this opportunity and become one of the leaders in the space. I am impressed by the strength of the company's medicinal chemistry and by the progress made in advancing high-quality clinical assets. The emerging clinical data, notably the results showing early proof of clinical concept for APR-1051, reinforce the potential of this approach."
Extensive Industry Experience
Dr. Kennedy currently serves as Chief Medical Officer (fractional) at Percheron Therapeutics (搜索) where he is responsible for clinical development and regulatory strategy, including the advancement of a Phase 2 program for a novel immuno-oncology checkpoint inhibitor. His previous roles include Chief Medical Officer positions at several biotechnology companies where he achieved significant regulatory and clinical milestones.
At Carisma Therapeutics, he executed the company's first-in-human clinical trial of a CAR-monocyte cellular therapy for cancer, established an international collaboration with a China-based biotechnology company for a Phase 1 cell therapy program, and developed the path-to-clinic strategy for a novel biologic targeting MASH and liver fibrosis. During his tenure at Galera Therapeutics (搜索), he advanced the filing of an NDA with the U.S. FDA for a first-in-class therapy for radiation-induced severe oral mucositis.
At Innovative Cellular Therapeutics, Dr. Kennedy developed and filed a first-in-human IND for a solid tumor CAR T-cell therapy, supported technology transfer and U.S. based manufacturing scale-up, and helped establish the company's U.S. clinical and investor presence. He also held multiple senior leadership roles at Lumos Pharma and NewLink Genetics, where he oversaw more than a dozen oncology clinical trials ranging from first-in-human Phase 1 studies through Phase 3 programs.
Academic and Clinical Foundation
Before entering industry, Dr. Kennedy built a successful academic and clinical career as a surgical oncologist. He served as Associate Professor of Surgery and Chief of the Section of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University, where he co-directed a multidisciplinary cancer program, led clinical and translational research programs in pancreatic cancer, and implemented institution-wide care pathways that improved patient outcomes.
Earlier academic appointments included faculty roles at Louisiana State University and The Johns Hopkins Hospital, where he completed extensive training in surgical oncology and conducted bench research in immuno-oncology focused on checkpoint inhibitors. Dr. Kennedy earned an MD from the Medical College of Virginia and is board-certified in surgery.
Aprea's DNA Damage Response Platform
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. The company's technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal, prostate, and breast cancers.
The company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 (搜索) kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.